1. Metabolic Enzyme/Protease
  2. PAI-1

PAI-1

Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), and functionally serves to suppress tissue and plasma fibrinolysis.

PAI-1 is a member of the serpin family of proteins and exists in multiple conformations of which a minor component, the “active” form, exhibits inhibitory effects against tPA and uPA.

PAI-1 is an endogenous inhibitor of urokinase-type plasminogen activator (uPA), and its expression is regulated by a number of intrinsic factors (e.g., cytokines and growth factors) and extrinsic factors (e.g., cellular stress).

PAI-1 seems to play a pivotal role in tumor growth and may represent a potential therapeutic target for bladder cancer.

PAI-1 Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-15253
    Tiplaxtinin Inhibitor
    Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 2.7 μM.
  • HY-101761
    TM5441 Inhibitor 98.34%
    TM5441 is a plasminogen activator inhibitor-1 (PAI-1); inhibits several tumor cell lines with IC50 values between 9.7 and 60.3 μM.
  • HY-100447
    TM5275 sodium Inhibitor 99.05%
    TM5275 sodium is a plasminogen activator inhibitor (PAI-1) with an IC50 of 6.95 μM.
  • HY-N1504
    Loureirin B Inhibitor
    Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC50 of 26.10 μM; Loureirin B also inhibits KATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.